Medicine and Dentistry
Patient
100%
Diffuse Large B-Cell Lymphoma
69%
Diagnosis
39%
Neoplasm
38%
Diagnostics
32%
Rituximab
28%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
28%
Doxorubicin
25%
microRNA 34a
23%
Isocitrate Dehydrogenase
23%
Enzyme
23%
Glioblastoma
23%
Cells
23%
Oligoastrocytoma
23%
Female
23%
Brain Tumor
23%
Prognosis
23%
Vacuolization
23%
Somatics
23%
Syndrome
23%
Fatigue
23%
Fever
23%
Overall Survival
21%
Survival
20%
Gene
19%
Ganglioglioma
18%
Hazard Ratio
17%
Progression Free Survival
14%
Next Generation Sequencing
13%
Symptom
12%
Radiation Therapy
10%
Proportional Hazards Model
9%
Therapeutic Procedure
8%
microRNA
7%
Injury
7%
Examination
7%
Cancer Therapy
7%
Hypogonadism
7%
Surgery
7%
Chemotherapy
7%
Magnetic Resonance Imaging
7%
Diagnostic Imaging
7%
Physician
7%
Tissues
7%
Family
7%
Low Back Pain
7%
Anodyne
7%
Sequela
7%
Neurosurgery
7%
Follow up
7%
Neuroscience
B Cell
69%
Lymphoma
69%
CHOP
28%
Rituximab
28%
Doxorubicin
25%
CXCR4
23%
Isocitrate Dehydrogenase
23%
Astrocytoma
23%
microRNA 34a
23%
Glioma
18%
Cell Line
11%
MicroRNA
7%
Immunohistochemistry
7%
Gene
7%
Phenotype
5%
Vincristine
5%
Cyclophosphamide
5%
In Vitro
5%
FOXP1
5%
Biochemistry, Genetics and Molecular Biology
Isocitrate Dehydrogenase
23%
B Cell
23%
Doxorubicin
23%
Survival
18%
Sample
12%
Overall Survival
7%
MicroRNA
5%
Gene Signature
5%
